HFF Inc (HF) Drops 9.06% on February 08

Equities Staff |

HFF Inc (HF) was one of the Russell 2000's biggest losers for Monday February 08 as the stock slid 9.06% to $23.48, a loss of $-2.34 per share. Starting at an opening price of $25.53 a share, the stock traded between $23.08 and $25.53 over the course of the trading day. Volume was 329,408 shares over 2,617 trades, against an average daily volume of 298,194 shares and a total float of 37.84 million.

The losses send HFF Inc down to a market cap of $888.38 million. In the last year, HFF Inc has traded between $47.77 and $24.63, and its 50-day SMA is currently $28.72 and 200-day SMA is $34.33.

The stock has a P/E Ratio of 12.8.

HFF Inc is a full-service commercial real estate financial intermediary. The Company provides commercial real estate and capital markets services to both the users and provides capital in the U.S. commercial real estate industry.

HFF Inc is based out of Pittsburgh, PA and has some 721 employees. Its CEO is Mark D. Gibson.

For a complete fundamental analysis analysis of HFF Inc, check out Equities.com’s Stock Valuation Analysis report for HF. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…